MIRA Pharmaceuticals, Inc.

Developing the next generation FDA approved novel synthetic THC analog

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a life sciences company focused on the development of MIRA1a, a novel synthetic THC analog. MIRA1a is being developed to treat anxiety and cognitive decline in the elderly and neuropathic pain without impurities or the negative side effects associated with cannabis plant extracts. MIRA1a is classified as an unscheduled drug by the U.S. Drug Enforcement Administration (DEA).

View MIRA1a Video

Improved Therapies with Potential Results

With one small change, MIRA's technology focuses on big effects that minimize the negative effects of THC, opening up new markets for indications and patients.

Making a Better Molecule

Our key candidate, MIRA1a, is being developed as the first prescription drug to target neuropathic pain and anxiety and improved cognition with enhanced bioavailability while offering higher potency and safety.

Learn About MIRA1a

Investor Relations

MIRA Pharmaceuticals, Inc.